来源：上海证券报·中国证券网 来源：上海证券报·中国证券网 上证报中国证券网讯 1月5日，创业板指盘中涨超2%，沪指重返4000点。截至10时33分，沪指涨 0.84%，深证成指涨1.66%，创业板指涨2.14%。全市场近4000只个股飘红。 盘面上看，脑机接口概念早盘大幅拉升，倍益康30CM涨停，三博脑科、翔宇医疗、伟思医疗、熵基科 技、爱朋医疗、诚益通20CM涨停。保险、游戏、半导体、风电设备等板块涨幅居前。 上证报中国证券网讯 1月5日，创业板指盘中涨超2%，沪指重返4000点。截至10时33分，沪指涨 0.84%，深证成指涨1.66%，创业板指涨2.14%。全市场近4000只个股飘红。 盘面上看，脑机接口概念早盘大幅拉升，倍益康30CM涨停，三博脑科、翔宇医疗、伟思医疗、熵基科 技、爱朋医疗、诚益通20CM涨停。保险、游戏、半导体、风电设备等板块涨幅居前。 ...

来源：上海证券报·中国证券网 来源：上海证券报·中国证券网 上证报中国证券网讯 1月5日，上证指数盘中重返4000点。截至10时27分，上证指数涨0.89%，深证成指 涨1.55%，创业板指涨1.97%。脑机接口概念早盘大幅拉升，倍益康30CM涨停，三博脑科、翔宇医疗、 伟思医疗、熵基科技、爱朋医疗、诚益通20CM涨停。 上证报中国证券网讯 1月5日，上证指数盘中重返4000点。截至10时27分，上证指数涨0.89%，深证成指 涨1.55%，创业板指涨1.97%。脑机接口概念早盘大幅拉升，倍益康30CM涨停，三博脑科、翔宇医疗、 伟思医疗、熵基科技、爱朋医疗、诚益通20CM涨停。 ...

脑机接口概念股集体暴涨。 公历2026年首个交易日（1月5日）上午，A股市场强劲上行，其中上证指数向上突破4000点整数大关。 在上周五（1月2日）大涨后，上午港股市场涨势趋缓。 值得注意的是，受到相关消息提振，上午A股市场和港股市场的脑机接口概念股集体暴涨，相关个股掀涨停潮。 沪指冲上4000点 公历2026年首个交易日上午，A股市场强劲上行，主要指数不同程度上涨，截至中午收盘，上证指数涨超1%，报4011.45点，再次站上 4000点整数大关；深证成指涨近2%。 | 今开 | 3986.97 | 最高 | | 4011.75 | 成交量 | 3.82亿手 | 涨跌额 | +42.61 | 振幅 | | 0.71% | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 昨收 | 3968.84 | 最低 | | 3983.57 | 成交额 | 6913.62亿 V | 涨跌幅 | +1.07% | 量比 | | 1.47 | | 分时 | 五日 | 日K | 園K | 月к | 更多v | | | ６ 高级 ...

Core Viewpoint - Neuralink, founded by Elon Musk, is set to begin large-scale production of its brain-machine interface technology this year, marking a significant advancement in automated surgical procedures and bringing previously speculative technology into mass production [1][4]. Company Developments - Neuralink has announced that it will automate surgical processes, reducing the insertion time for its devices to 1.5 seconds and cutting manufacturing costs by 95% [4]. - As of September 2025, 12 patients with severe paralysis have successfully implanted Neuralink devices, enabling them to perform tasks such as gaming and social media interaction [5]. - The company raised $650 million (approximately 4.55 billion RMB) in a funding round completed in June [5]. Industry Trends - The brain-machine interface sector is experiencing a surge in interest and investment, with companies like阶梯医疗, 博睿康, and 芯智达 entering clinical validation stages [9]. - The Chinese government has included brain science and related research in its "14th Five-Year Plan," aiming for significant technological breakthroughs by 2027 [10]. - The market for brain-machine interfaces in China is projected to grow from 3.2 billion RMB in 2024 to over 5.5 billion RMB by 2027, with global market estimates reaching $40 billion by 2030 [11]. Market Response - Following Neuralink's announcement, stocks related to brain-machine interfaces surged, with notable increases in companies such as 南京熊猫电子股份 (up 43.69%) and 微创脑科学 (up 16.19%) [2][3]. - A-share market also saw significant gains, with multiple companies hitting the upper limit of their trading range [2]. Future Outlook - Neuralink's roadmap includes plans for motion decoding for patients with spinal injuries and visual encoding for those with vision impairments, potentially addressing mental health issues and enhancing cognitive abilities [6]. - The industry is expected to benefit from technological breakthroughs, policy support, and collaborative ecosystems, with a projected CAGR of 17% from 2025 to 2034 [11].

1月5日，A股迎来2026年的首个交易日，三大指数集体高开。沪指高开0.46%，深成指高开0.80%，创业 板指高开0.84%，A股迎来开门红。 板块方面，人脑工程、贵金属、石油石化等板块指数涨幅居前。 其中，脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨停，倍益康、爱朋医疗、 翔宇医疗涨超10%。消息面上，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开 始对脑机接口设备进行"大规模生产"。 另外，早盘商业航天概念大面积高开，金风科技、雷科防务、联创光电等多股涨停，久之洋、北斗星 通、中国卫星、顺灏股份等高开超5%。消息面上，12月31日，上交所官网显示，蓝箭航天科创板IPO获 受理，正式冲刺"商业火箭第一股"。 值得一提的是，就在明日，A股市场还将迎来首只上市新股，同日还有两只新股开启申购。 随着马年春节的临近，资本市场将会怎么走？各大券商也纷纷做出预测。 中信证券称，增量资金入市不会是2026年市场迈上一个新台阶的主要因素。2026年最大的预期差来自于 外需与内需的平衡，对外"征税"、补贴内需应是大势所趋，今年是个重要的开端。站在开年，考虑到去 年末的资金热 ...

北京商报讯(记者丁宁)1月5日，脑机接口概念股走强，其中，三博脑科（301293）、美好医疗 （301363）、翔宇医疗"20cm"涨停，创新医疗（002173）同样涨停，爱朋医疗（300753）、博拓生物 等涨超10%。 ...

每经AI快讯，1月5日，沪指高开0.46%，深成指高开0.80%，创业板指高开0.84%，人脑工程、贵金属、 石油石化等板块指数涨幅居前。脑机接口概念表现活跃，创新医疗涨停，美好医疗、三博脑科20cm涨 停，倍益康、爱朋医疗、翔宇医疗涨超10%，博拓生物、伟思医疗跟涨。 （文章来源：每日经济新闻） ...

更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 脑机接口深度报告 20260104 摘要 Q&A 更多资料加入知识星球:水木调研纪要 关注公众号:水木纪要 接口的医保价格进行了单独立项,并有 11个省份跟进了相关费用的设定。7月 份,工信部联合七部门发布了《脑机接口推动产业创新发展实施意见》,在全国 范围内推广两步走的产业目标,并强调非侵入式产品在工业制造和安全生产中的 应用。10月28日,《十五规划建议》将脑机接口列为六大未来产业之一,并定 位为新的经济增长点。12月26日,国家药监局将植入式脑机接口器械纳入优先 审批高端医疗器械目录,这将加快相关产品的注册审批流程。 脑机接口全球市场规模如何测算? 我们对全球脑机接口市场规模进行了详细测算,将其划分为医疗和消费教育两大 类市场。目前医疗健康场景是主要关注点,包括运动功能障碍重建、语言功能障 碍重建、视觉障碍功能重建以及意识和认知障碍恢复等应用场景。在这些领域, 我们针对中风、癫痫、脊髓损伤、帕金森等疾病患者进行了渗透率假设。例如, 到 2030 年帕金森病领域渗透率预计可达 15%,到 2040 年整体渗透率可达到 15-20%。 消费教育领域虽 ...

Group 1: Event Overview - The 2025 Technology Innovation Sharing Conference hosted by Luo Yonghao was held in Shanghai on December 30, but he arrived over 40 minutes late [1] - Luo announced a full refund for ticket prices ranging from 300 to 1000 yuan and apologized, stating he would write a confession letter [3] Group 2: ADHD and Treatment Insights - Luo Yonghao revealed that his tardiness was related to ADHD, a condition he has suffered from for over a decade [3][7] - According to the 2023 edition of the "Chinese Adult ADHD Diagnosis and Treatment Expert Consensus," the prevalence of ADHD among adults in China is approximately 3% [5] - Current treatments for ADHD include medication, psychological therapy, and behavioral training, with medication being the most effective [5][9] Group 3: Medication Landscape - The primary medication for ADHD in China is methylphenidate, marketed as "Zhuanzhu Da," which is the only approved import for this treatment in the past 20 years [5][9] - The long-acting formulation of methylphenidate has shown significant efficacy and is recommended as a first-line treatment for adult ADHD patients [9] - The market for ADHD medications is expanding, with sales in domestic sample hospitals reaching approximately 350 million yuan in 2023, and further growth to about 430 million yuan in the first three quarters of 2024 [11] Group 4: Market Dynamics and Competition - The introduction of the first generic version of methylphenidate by Lifan Pharmaceutical in September 2023 has broken the 20-year monopoly of "Zhuanzhu Da" [11][12] - Other companies, such as China Resources Double Crane and Suzhou First Pharmaceutical, hold production licenses for regular formulations of methylphenidate, but these are less effective than the sustained-release versions [12] - New drug developments are underway, including a potential first-in-class medication for ADHD currently in clinical trials [12]

Group 1: Event Overview - The 2025 Technology Innovation Sharing Conference hosted by Luo Yonghao was held in Shanghai, but he arrived over 40 minutes late [1] - Luo Yonghao announced a full refund for ticket prices ranging from 300 to 1000 yuan and apologized, stating he would write a confession letter [4] Group 2: ADHD and Treatment Insights - According to the 2023 edition of the "Expert Consensus on the Diagnosis and Treatment of Adult ADHD in China," the prevalence of ADHD among adults in China is approximately 3% [3][6] - The primary treatment methods for ADHD include medication, psychotherapy, and behavioral training, with medication being one of the most effective approaches [3][8] - The medication mentioned by Luo Yonghao, "Zhuanzhu Da," is a sustained-release formulation of methylphenidate, which is a first-line treatment for ADHD [3][8] Group 3: Challenges in ADHD Treatment - There is currently no short-term cure for ADHD, and it requires long-term management and comprehensive treatment [5][9] - The existing treatment landscape in China lacks superior alternative medications, with the only approved sustained-release methylphenidate product being "Zhuanzhu Da," which has been on the market since 2005 [8][11] - The supply of "Zhuanzhu Da" has faced instability, leading to medication shortages and anxiety among patients and their families [9] Group 4: Market Dynamics and Developments - The sales revenue for ADHD medications in domestic sample hospitals was approximately 350 million yuan in 2023, with a further increase to about 430 million yuan in the first three quarters of 2024 [10] - Domestic pharmaceutical companies are increasingly focusing on the ADHD treatment market, with Lifan Pharmaceutical launching the first generic version of sustained-release methylphenidate, breaking a 20-year monopoly [11] - Other companies, such as Huazhong Shuanghe and Suzhou No. 1 Pharmaceutical, hold production licenses for regular formulations of methylphenidate, but these are less effective than sustained-release versions [11]